demonstr human leukocyt degranul induc sera homozygot heterozygot cystic fibrosi abil epsilonamino caproic acid eacatr normal serum cystic fibrosi cfaffect carrier sera promot releas lysosom enzym sensit human polymorphonuclear leukocyt pmn wa assess measur beta glucuronidas myeloperoxidas activ exposur cell variou test sera thi studi wa initi extend analog preciliari dyskinesia factor precdf separ cellfre media cultur deriv cf homozyg heterozyg individu c3a anaphylatoxin extent lysosom degranul human pmn expos fresh untreat sera five control seven cf homozygot eight heterozygot express amount betaglucuronidas releas wa 784 0934 control sera 1401 179 cfaffect sera 1061 143 heterozyg sera differ cf homozygot control subject signific p less 00001 differ cf affect carrier individu 0001 less p less 0005 control subject carrier 0001 less p less 0005 betaglucuronidas howev differ control subject cf heterozyg individu signific treatment sera 1 eaca gave valu betaglucuronidas myeloperoxidas releas slightli reduc compar obtain fresh untreat sampl eaca appar reduc activ betaglucuronidas releas pmn amicon filtrat studi serum sampl demonstr degranul abil presenc cilicari dyskinesia assess rabbit tracheal bioassay alway associ therefor relationship precdf degranul activ nativ cfaffect carrier sera unclear part becaus limit inher test system employ